---
layout: default
title: Ranolazine
parent: Model Prediction Only (L5)
nav_order: 498
evidence_level: L5
indication_count: 1
---

# Ranolazine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ranolazine: From an Undocumented Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis

## One-Sentence Summary

> The evidence pack does not currently document Ranolazine's original licensed indication or mechanism of action.
> The TxGNN model predicts a possible new role in **Nephrogenic Syndrome of Inappropriate Antidiuresis**,
> but this prediction is currently supported by **no registered clinical trials** and **no published literature** — it rests on the computational model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in the evidence pack (no UK licence text available) |
| Predicted New Indication | Nephrogenic syndrome of inappropriate antidiuresis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for Ranolazine is not currently available in this evidence pack, and no original indication text has been supplied. As a result, it is not possible to construct a mechanistic rationale linking Ranolazine to nephrogenic syndrome of inappropriate antidiuresis at this time — the `repurposing_rationale` fields (mechanistic link, similarity to original indication) are explicitly marked as pending in the source data.

The predicted association currently derives solely from the TxGNN knowledge-graph model score (99.65%, rank 3973), without corroborating clinical trial data, published literature, or an established pharmacological mechanism. This should be treated as a hypothesis-generating signal only, not as evidence of clinical plausibility.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## UK Market Information

Ranolazine currently holds no UK marketing authorisations in this evidence pack (market status: not marketed; total licences: 0). No product or indication information is therefore available to summarise.

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate lacks the minimum data required for a safety and mechanistic assessment — original indication, mechanism of action, UK licensing status, and supporting clinical/literature evidence are all absent. A blocking data gap (missing SmPC-derived warnings/contraindications) prevents even an initial safety screen from being completed.

**To proceed, the following is needed:**
- SmPC-derived warnings, contraindications and drug interaction data (currently blocking)
- Mechanism of action data via DrugBank API query
- Confirmation of original licensed indication(s), whether in the UK or another jurisdiction
- Clinical trial and literature searches specific to nephrogenic syndrome of inappropriate antidiuresis
- UK/MHRA licensing status verification if commercial development is being considered
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

